drugset / Trial / NCT05053035
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A phase 2 double-blind, placebo-controlled study of AL001 in participants with C9orf72-associated ALS.
Timeline
- Start
- 2021-09-02
- Primary completion
- 2022-10-28
- Completion
- 2022-10-28
Outcome
Outcome not reported
Stopped: “The Sponsor is considering a subsequent study in ALS, potentially with different inclusion/exclusion criteria.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Latozinemab | Monoclonal antibody | — | Intravenous |